Author:

Fujisawa Healthcare, Inc.

Date: 16 March 2005

Abstract:

Deerfield, Ill., March 16, 2005– Fujisawa Healthcare, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the use of micafungin sodium, the antifungal product for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and the treatment ofesophageal candidiasis. The newly approved agent will be marketed in the United States under the name Mycamineâ„¢ (micafungin sodium for injection).

Link to DOI

Download the full article (Disclaimer)

This manuscript library of ~16,000 articles (1729-2024) related to Aspergillus and aspergillosis is intended for individual study only, and is provided as contribution to global understanding of the topic. Please refer to the publisher’s guidance about any other usage.

I understand (click to accept and view download link)

---